Jonathan B. Orens, MD

Primary Academic Title

Professor of Medicine

Background

Centers and Institutes

Comprehensive Transplant Center

Clinical Trials Summary

Genome Transplant Dynamics

Research Interests

Chronic allograft rejection, Clinical outcomes of lung transplantation, Ischemic reperfusion injury ("primary graft dysfunction")

Lab Website

Jonathan Orens Lab

• Research in the Jonathan Orens Lab examines topics such as clinical outcomes of lung transplantation, chronic allograft rejection and ischemic reperfusion injury, also known as primary graft dysfunction.

Research Summary

Dr. Orens’ research interests are focused on lung transplantation. He is particularly interested in lung transplant outcomes specifically assessing risk factors for the development of chronic allograft rejection and primary graft dysfunction and developing new treatment strategies for these problems. Dr. Orens is internationally recognized as an expert in the care and management of lung transplant recipients.  He was the first to discover the benefit of treating lung allograft dysfunction with the macrolide antibiotic Azithromycin which is now a standard of care in lung transplantation.  He was the first author of the 2006 International Guidelines for the Selection of Lung Transplant Candidates.  He currently participates in several lung transplant research consortia including the NIH-sponsored Lung Transplant Outcomes Group, the NIH Genomic Research Alliance for Transplant, and an NIH-sponsored Clinical Trials in Organ Transplant program.

Selected Publications

• Diamond JM, Akimova T, Kazi A, Shah RJ, Cantu E, Feng R, Levine MH, Kawut SM, Meyer NJ, Lee JC, Hancock WW, Aplenc R, Ware LB, Palmer SM, Bhorade S, Lama VN, Weinacker A, Orens J, Wille K, Crespo M, Lederer DJ, Arcasoy S, Demissie E, Christie JD; for the Lung Transplant Outcomes Group. “Genetic variation in prostaglandin E2 pathway is associated with primary graft dysfunction.” Am J Respir Crit Care Med. 2014 Jan 27. [Epub ahead of print].

• Diamond JM, Lee JC, Kawut SM, Shah RJ, Localio AR, Bellamy SL, Lederer DJ, Cantu E, Kohl BA, Lama VN, Bhorade SM, Crespo M, Demissie E, Sonett J, Wille K, Orens J, Shah AS, Weinacker A, Arcasoy S, Shah PD, Wilkes DS, Ware LB, Palmer SM, Christie JD; Lung Transplant Outcomes Group. “Clinical risk factors for primary graft dysfunction after lung transplantation.” Am J Respir Crit Care Med. 2013 Mar 1;187(5):527-34. doi: 10.1164/rccm.201210-1865OC. Epub 2013 Jan 10.

• Diamond JM, Porteous MK, Cantu E, Meyer NJ, Shah RJ, Lederer DJ, Kawut SM, Lee J, Bellamy SL, Palmer SM, Lama VN, Bhorade SM, Crespo M, Demissie E, Wille K, Orens J, Shah PD, Weinacker A, Weill D, Arcasoy S, Wilkes DS, Ware LB, Christie JD; Lung Transplant Outcomes Group. “Elevated plasma angiopoietin-2 levels and primary graft dysfunction after lung transplantation.” PLoS One. 2012;7(12):e51932. doi: 10.1371/journal.pone.0051932. Epub 2012 Dec 19.

• Eberlein M, Reed RM, Bolukbas S, Parekh KR, Arnaoutakis GJ, Orens JB, Brower RG, Shah AS, Hunsicker L, Merlo CA. “Lung size mismatch and survival after single and bilateral lung transplantation.” Ann Thorac Surg. 2013 Aug;96(2):457-63. doi: 10.1016/j.athoracsur.2013.04.064. Epub 2013 Jun 26.

• Eberlein M, Reed RM, Maidaa M, Bolukbas S, Arnaoutakis GJ, Orens JB, Brower RG, Merlo CA, Hunsicker LG. “Donor-recipient size matching and survival after lung transplantation: A cohort study.” Ann Am Thorac Soc. 2013 Oct;10(5):418-25. doi: 10.1513/AnnalsATS.201301-008OC.

• Miller HL, Shah PD, Orens JB, McDyer JF. “Prevention of airway allograft tolerance by polyinosinic: Polycytidylic acid requires type I interferon responsiveness for mouse airway obliteration.” J Heart Lung Transplant. 2013 Sep;32(9):914-24. doi: 10.1016/j.healun.2013.06.017.

• Shah P, Orens JB. “Impact of nutritional state on lung transplant outcomes: The weight of the evidence.” J Heart Lung Transplant. 2013 Aug;32(8):755-6. doi: 10.1016/j.healun.2013.06.001.

• Shah RJ, Diamond JM, Cantu E, Lee JC, Lederer DJ, Lama VN, Orens J, Weinacker A, Wilkes DS, Bhorade S, Wille KM, Ware LB, Palmer SM, Crespo M, Localio AR, Demissie E, Kawut SM, Bellamy SL, Christie JD. “Latent class analysis identifies distinct phenotypes of primary graft dysfunction after lung transplantation.” Chest. 2013 Aug;144(2):616-22. doi: 10.1378/chest.12-1480.

• Shah RJ, Wickersham N, Lederer DJ, Palmer SM, Cantu E, Diamond JM, Kawut SM, Lama VN, Bhorade S, Crespo M, Demissie E, Sonett J, Wille K, Orens J, Weinacker A, Shah P, Arcasoy S, Wilkes DS, Christie JD, Ware LB; Lung Transplant Outcomes Group. “Preoperative plasma club (clara) cell secretory protein levels are associated with primary graft dysfunction after lung transplantation.” Am J Transplant. 2014 Feb;14(2):446-52. doi: 10.1111/ajt.12541. Epub 2014 Jan 8. 

• Yarmus L, Akulian J, Gilbert C, Illei P, Shah P, Merlo C, Orens J, Feller-Kopman D. “Cryoprobe transbronchial lung biopsy in patients after lung transplantation: A pilot safety study.” Chest. 2013 Mar;143(3):621-6.

Memberships

• Committee on the Promotion of the Clinical Program Builder and Innovator, Johns Hopkins School of Medicine